Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non‐Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study
Thoracic Cancer · 2026-04 · 17 (7)
DOI: 10.1111/1759-7714.70269 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thoracic Cancer, online erschienen am 30.03.2026. Verfasst von Toshiaki Takakura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine III, Wakayama Medical University, Wakayama, Wakayama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
The addition of immune checkpoint inhibitor (ICI) to platinum‐based chemotherapy has improved outcomes in patients with advanced non‐small cell lung cancer (NSCLC). However, evidence on the efficacy of adding ICI to platinum retreatment in patients who relapse after perioperative platinum‐based chemotherapy remains limited.
Methods
We retrospectively analyzed patients with recurrent NSCLC following perioperative platinum‐based chemotherapy. Patients were categorized into either the “chemo group,” who received platinum retreatment without ICI, or the “ICI‐chemo group,” who received platinum retreatment with ICI. The primary endpoint was progression‐free survival in patients treated with ICI.
Results
Among 124 patients who received perioperative platinum therapy and surgery, 31 underwent platinum retreatment: 17 in the chemo group and 14 in the ICI‐chemo group. PFS was significantly longer in the ICI‐chemo group than in the chemo group (15.4 vs. 5.9 months; log‐rank p = 0.023; HR 0.40, 95% CI, 0.18–0.90). Among patients with PD‐L1 ≥ 50%, the ICI‐chemo group showed a greater trend toward longer PFS compared with the chemo group (16.9 vs. 4.0 months; HR 0.11, 95% CI, 0.01–1.05).
Conclusions
Adding ICI to platinum retreatment may be an effective option for patients with NSCLC who relapse after perioperative chemotherapy, particularly in those with PD‐L1 expression ≥ 50%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine III, Wakayama Medical University, Wakayama, Wakayama, Japan.
- Department of Pulmonary Medicine, Hashimoto Municipal Hospital, Hashimoto, Wakayama, Japan.
- Department of Respiratory Medicine, NHO Minami Wakayama Medical Center, Tanabe, Wakayama, Japan.
- Department of Respiratory Medicine, NHO Wakayama Medical Hospital, Hidaka-gun, Wakayama, Japan.
- Department of Respiratory Medicine, Naga Municipal Hospital, Kinokawa, Wakayama, Japan.
ORCID-Profile: Toshiaki Takakura, Ryota Shibaki, Hiroaki Akamatsu, Nobuyuki Yamamoto
Zitieren
APA
Takakura, T., Shibaki, R., Washioka, A., Murakami, Y., Harutani, Y., Akamatsu, H., & Yamamoto, N. (2026). Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non‐Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study. Thoracic Cancer, 17(7). https://doi.org/10.1111/1759-7714.70269
Vancouver
Takakura T, Shibaki R, Washioka A, Murakami Y, Harutani Y, Akamatsu H, et al. Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non‐Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study. Thoracic Cancer. 2026;17(7). doi:10.1111/1759-7714.70269
BibTeX
@article{Takakura2026,
author = {Takakura, Toshiaki and Shibaki, Ryota and Washioka, Atsushi and Murakami, Yusuke and Harutani, Yuhei and Akamatsu, Hiroaki and Yamamoto, Nobuyuki},
title = {Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non‐Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {7},
doi = {10.1111/1759-7714.70269}
}
EUVIMED